Human serum albumin-based nanoparticle-mediated in vitro gene delivery

PLoS ONE

Volumn 9, Issue 9, 2014, Pages

  Langiu, Monica ^a   Dadparvar, Miriam ^a   Kreuter, Jörg ^a   Ruonala, Mika O ^a  

^a GOETHE UNIVERSITY   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

COMPLEMENTARY DNA; HUMAN SERUM ALBUMIN; LUCIFERASE; NANOPARTICLE; POLYETHYLENEIMINE; VIRUS VECTOR; DNA; DRUG CARRIER; SERUM ALBUMIN;

ARTICLE; BLOOD BRAIN BARRIER; CELL MEMBRANE; CELLULAR DISTRIBUTION; CEREBELLUM CELL; DEGENERATIVE DISEASE; DOT HYBRIDIZATION; DRUG DELIVERY SYSTEM; FEASIBILITY STUDY; FLUORESCENCE ACTIVATED CELL SORTING; GENE DELIVERY SYSTEM; GENE TARGETING; GENE THERAPY; GENETIC TRANSFECTION; HELA CELL LINE; HUMAN; IMMUNE RESPONSE; IMMUNOFLUORESCENCE; IN VITRO STUDY; INFLAMMATION; MOUSE; NONHUMAN; PROTEIN EXPRESSION; SCANNING ELECTRON MICROSCOPY; ANIMAL; CEREBELLUM; CHEMISTRY; CYTOLOGY; ENDOCYTOSIS; GENETICS; METABOLISM; NERVE CELL; PARTICLE SIZE; PLASMID;

ANIMALS; CEREBELLUM; DNA; DRUG CARRIERS; ENDOCYTOSIS; HELA CELLS; HUMANS; MICE; NANOPARTICLES; NEURONS; PARTICLE SIZE; PLASMIDS; POLYETHYLENEIMINE; SERUM ALBUMIN; TRANSFECTION;

EID: 84907189685     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0107603     Document Type: Article

References (36)

1. Coppede F, Mancuso M, Siciliano G, Migliore L, Murri L (2006) Genes and the environment in neurodegeneration. Biosci Rep 26: 341-367.
2. Beck M (2007) New therapeutic options for lysosomal storage disorders: enzyme replacement, small molecules and gene therapy. Hum Genet 121: 1-22.
3. Kreuter J (2004) Influence of the surface properties on nanoparticle-mediated transport of drugs to the brain. J Nanosci Nanotechnol 4: 484-488.
4. Begley DJ (1996) The blood-brain barrier: principles for targeting peptides and drugs to the central nervous system. J Pharm Pharmacol 48: 136-146.
5. Brightman MW, Kadota Y (1992) Nonpermeable and permeable vessels of the brain. NIDA Res Monogr 120: 87-107.
6. Sondhi D, Johnson L, Purpura K, Monette S, Souweidane MM, et al. (2012) Long-term expression and safety of administration of AAVrh.10hCLN2 to the brain of rats and nonhuman primates for the treatment of late infantile neuronal ceroid lipofuscinosis. Human gene therapy methods 23: 324-335.
7. Sondhi D, Hackett NR, Peterson DA, Stratton J, Baad M, et al. (2007) Enhanced survival of the LINCL mouse following CLN2 gene transfer using the rh.10 rhesus macaque-derived adeno-associated virus vector. Molecular therapy: The journal of the American Society of Gene Therapy 15: 481-491.
8. Passini MA, Dodge JC, Bu J, Yang W, Zhao Q, et al. (2006) Intracranial delivery of CLN2 reduces brain pathology in a mouse model of classical late infantile neuronal ceroid lipofuscinosis. The Journal of neuroscience: The official journal of the Society for Neuroscience 26: 1334-1342.
9. Crystal RG, Sondhi D, Hackett NR, Kaminsky SM, Worgall S, et al. (2004) Clinical protocol. Administration of a replication-deficient adeno-associated virus gene transfer vector expressing the human CLN2 cDNA to the brain of children with late infantile neuronal ceroid lipofuscinosis. Human gene therapy 15: 1131-1154.
10. Verma IM, Somia N (1997) Gene therapy - promises, problems and prospects. Nature 389: 239-242.
11. Somia N, Verma IM (2000) Gene therapy: Trials and tribulations. Nat Rev Genet 1: 91-99.
12. Rhaese S, von Briesen H, Rubsamen-Waigmann H, Kreuter J, Langer K (2003) Human serum albumin-polyethylenimine nanoparticles for gene delivery. J Control Release 92: 199-208.
13. Wagner S, Zensi A, Wien SL, Tschickardt SE, Maier W, et al. (2012) Uptake mechanism of ApoE-modified nanoparticles on brain capillary endothelial cells as a blood-brain barrier model. PLoS One 7: e32568.
14. Zensi A, Begley D, Pontikis C, Legros C, Mihoreanu L, et al. (2010) Human serum albumin nanoparticles modified with apolipoprotein A-I cross the bloodbrain barrier and enter the rodent brain. J Drug Target 18: 842-848.
15. Zensi A, Begley D, Pontikis C, Legros C, Mihoreanu L, et al. (2009) Albumin nanoparticles targeted with Apo E enter the CNS by transcytosis and are delivered to neurones. J Control Release 137: 78-86.
16. Steiniger SC, Kreuter J, Khalansky AS, Skidan IN, Bobruskin AI, et al. (2004) Chemotherapy of glioblastoma in rats using doxorubicin-loaded nanoparticles. Int J Cancer 109: 759-767.
17. Langer K, Balthasar S, Vogel V, Dinauer N, von Briesen H, et al. (2003) Optimization of the preparation process for human serum albumin (HSA) nanoparticles. Int J Pharm 257: 169-180.
18. Wohlfart S, Khalansky AS, Gelperina S, Begley D, Kreuter J (2011) Kinetics of transport of doxorubicin bound to nanoparticles across the blood-brain barrier. Journal of controlled release: official journal of the Controlled Release Society 154: 103-107.
19. Kreuter J (2013) Drug delivery to the central nervous system by polymeric nanoparticles: What do we know? Adv Drug Deliv Rev.
20. Abbasi S, Paul A, Prakash S (2011) Investigation of siRNA-Loaded Polyethylenimine-Coated Human Serum Albumin Nanoparticle Complexes for the Treatment of Breast Cancer. Cell Biochem Biophys.
21. Lungwitz U, Breunig M, Blunk T, Gopferich A (2005) Polyethylenimine-based non-viral gene delivery systems. Eur J Pharm Biopharm 60: 247-266.
22. Langer K, Anhorn MG, Steinhauser I, Dreis S, Celebi D, et al. (2008) Human serum albumin (HSA) nanoparticles: reproducibility of preparation process and kinetics of enzymatic degradation. Int J Pharm 347: 109-117.
23. Cao Y, Espinola JA, Fossale E, Massey AC, Cuervo AM, et al. (2006) Autophagy is disrupted in a knock-in mouse model of juvenile neuronal ceroid lipofuscinosis. The Journal of biological chemistry 281: 20483-20493.
24. Schneider CA, Rasband WS, Eliceiri KW (2012) NIH Image to ImageJ: 25 years of image analysis. Nature methods 9: 671-675.
25. Steinhauser I, Langer K, Strebhardt K, Spankuch B (2009) Uptake of plasmidloaded nanoparticles in breast cancer cells and effect on Plk1 expression. J Drug Target 17: 627-637.
26. Goula D, Remy JS, Erbacher P, Wasowicz M, Levi G, et al. (1998) Size, diffusibility and transfection performance of linear PEI/DNA complexes in the mouse central nervous system. Gene therapy 5: 712-717.
27. Albanese A, Tang PS, Chan WC (2012) The effect of nanoparticle size, shape, and surface chemistry on biological systems. Annu Rev Biomed Eng 14: 1-16.
28. Moret I, Esteban Peris J, Guillem VM, Benet M, Revert F, et al. (2001) Stability of PEI-DNA and DOTAP-DNA complexes: effect of alkaline pH, heparin and serum. Journal of controlled release: official journal of the Controlled Release Society 76: 169-181.
29. Ungaro F, De Rosa G, Miro A, Quaglia F (2003) Spectrophotometric determination of polyethylenimine in the presence of an oligonucleotide for the characterization of controlled release formulations. Journal of pharmaceutical and biomedical analysis 31: 143-149.
30. Saha K, Kim ST, Yan B, Miranda OR, Alfonso FS, et al. (2013) Surface functionality of nanoparticles determines cellular uptake mechanisms in mammalian cells. Small 9: 300-305.
31. Lu W, Sun Q, Wan J, She Z, Jiang XG (2006) Cationic albumin-conjugated pegylated nanoparticles allow gene delivery into brain tumors via intravenous administration. Cancer research 66: 11878-11887.
32. Wohlfart S, Gelperina S, Kreuter J (2012) Transport of drugs across the bloodbrain barrier by nanoparticles. J Control Release 161: 264-273.
33. Demeneix B, Behr J, Boussif O, Zanta MA, Abdallah B, et al. (1998) Gene transfer with lipospermines and polyethylenimines. Adv Drug Deliv Rev 30: 85-95
34. Dadparvar M, Wagner S, Wien S, Kufleitner J, Worek F, et al. (2011) HI 6 human serum albumin nanoparticles-development and transport over an in vitro blood-brain barrier model. Toxicology letters 206: 60-66.
35. Ulbrich K, Knobloch T, Kreuter J (2011) Targeting the insulin receptor: nanoparticles for drug delivery across the blood-brain barrier (BBB). Journal of drug targeting 19: 125-132.
36. Ulbrich K, Hekmatara T, Herbert E, Kreuter J (2009) Transferrin- and transferrin-receptor-antibody-modified nanoparticles enable drug delivery across the blood-brain barrier (BBB). European journal of pharmaceutics and biopharmaceutics: official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik eV 71: 251-256